BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22241949)

  • 1. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R; Mashavi M; Zimlichman R
    Vasc Health Risk Manag; 2011; 7():749-59. PubMed ID: 22241949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan: widening indications for this angiotensin II receptor blocker?
    Mendis B; Page SR
    Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan cilexetil: an update.
    Joost A; Schunkert H; Radke PW
    Expert Opin Pharmacother; 2011 Aug; 12(11):1769-80. PubMed ID: 21651457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE; Jarvis B
    Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
    J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS
    J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
    Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
    Mengden T; Uen S; Bramlage P
    Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
    Ketelhut R; Bramlage P
    Clin Drug Investig; 2010; 30(5):301-11. PubMed ID: 20384386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ; Goa KL
    Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
    Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
    Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease.
    Tamura Y; Kosuga M; Yamashita M; Tomioka S; Sasaki M; Hikita T; Nakajima H; Kojima K; Uchida S
    Clin Exp Nephrol; 2008 Aug; 12(4):256-263. PubMed ID: 18317875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.